PharmaShots Weekly Snapshots (May 17 – 21, 2021)

 PharmaShots Weekly Snapshots (May 17 – 21, 2021)

BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Published: May 21, 2021 | Tags: BeiGene, Tislelizumab, CT, P-III, RATIONALE 309 Study, Recurrent, Metastatic Nasopharyngeal Cancer

Aurinia to Present Results of Lupkynis (voclosporin) in AURORA 2 Continuation Study for Lupus Nephritis at EULAR 2021

Published: May 21, 2021 | Tags: Aurinia, Lupkynis, voclosporin, AURORA 2 Continuation Study, Lupus Nephritis, EULAR 2021

Takeda Reports the US FDA’s Acceptance and Priority Review of Maribavir’s NDA for Post-Transplant CMV Infection

Published: May 21, 2021 | Tags: Takeda, US, FDA, Priority Review, Maribavir, NDA, Post-Transplant CMV Infection

Astellas and Seagen Report Updated Results of Padcev in Two Studies for Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Published: May 21, 2021 | Tags: Astellas, Seagen, Padcev, Two, Studies, Locally Advanced,  Metastatic Urothelial Cancer

AstraZeneca’s Vaxzevria (AZD1222) Receives Approval for Emergency Use in Japan to Treat COVID-19

Published: May 21, 2021 | Tags: AstraZeneca, Vaxzevria, AZD1222, Approval, Emergency Use, Japan COVID-19

Moderna’s COVID-19 Vaccine Receives Approval for Emergency Use in Japan

Published: May 21, 2021 | Tags: Moderna, COVID-19 Vaccine, Approval, Emergency Use, Japan

Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes

Published: May 20, 2021 | Tags: Lilly, Tirzepatide, SURPASS-4 Study, Type 2 Diabetes

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Published: May 20, 2021 | Tags: Janssen, Imbruvica, ibrutinib, Combination Regimen, Chronic Lymphocytic Leukemia, ASCO

Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

Published: May 20, 2021 | Tags: Allogene, ALLO-501, ALLO-501A, P-I, Studies, Relapsed/Refractory Non-Hodgkin Lymphoma

Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC

Published: May 20, 2021 | Tags: Janssen, Amivantamab, Lazertinib, P-I, CHRYSALIS Study, EGFR-Mutated NSCLC

Takeda Presents Results of Mobocertinib in P-I/II Study for Patients with EGFR Exon20 Insertion+ mNSCLC

Published: May 20, 2021 | Tags: Takeda, Mobocertinib, P-I/II, Study, EGFR Exon20 Insertion+ mNSCLC

Genentech Reports Results of Tecentriq in P-III IMpower010 Study for 1L Treatment of NSCLC

Published: May 20, 2021 | Tags: Genentech, Tecentriq, P-III, IMpower010 Study, NSCLC

BioXcel Reports the US FDA’s Acceptance of BXCL501’s NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II

Published: May 19, 2021 | Tags: BioXcel, US, FDA, BXCL501, NDA, Agitation, Schizophrenia, Bipolar Disorders I and II

BMS Extends its 2019 Collaboration with Exscientia for AI Driven Drug Discovery

Published: May 19, 2021 | Tags: BMS, Exscientia, AI, Driven Drug Discovery

Janssen Signs an Option and License Agreement with Mestag to Discover Novel Fibroblast Targets for Inflammatory Disease

Published: May 19, 2021 | Tags: Janssen, Mestag, Discover, Novel Fibroblast Targets, Inflammatory Disease

Glaukos Expands its Partnership with Santen for Preserflo MicroShunt

Published: May 19, 2021 | Tags: Glaukos, Partnership, Santen, Preserflo MicroShunt

Sarepta’s SRP-9001 Demonstrates Robust Expression and Safety Results in ENDEAVOR Study for DMD

Published: May 19, 2021 | Tags: Sarepta, SRP-9001, Robust Expression, Safety Results, ENDEAVOR Study, DMD

BMS Signs an Exclusive Global License with Agenus for its Anti-TIGIT Bispecific Antibody Program

Published: May 19, 2021 | Tags: BMS, Global License, Agenus, Anti-TIGIT, Bispecific Antibody Program

BlueRock Collaborates with Fujifilm and Opsis to Discover and Develop Cell Therapies for Eye Diseases

Published: May 18, 2021 | Tags: BlueRock, Fujifilm, Opsis, Discover, Develop, Cell Therapies, Eye Diseases

Medicago and GSK Report Results of Plant-Derived Vaccine in a P-II Study for COVID-19

Published: May 18, 2021 | Tags: Medicago, GSK, Plant-Derived Vaccine, P-II Study, COVID-19

Roche Receives the US FDA’s EUA for cobas SARS-CoV-2 Test to Suspect COVID-19

Published: May 18, 2021 | Tags: Roche, US, FDA, EUA, cobas SARS-CoV-2 Test, COVID-19

Eli Lilly and Innovent Report the US FDA’s Acceptance of Sintilimab + Chemotherapy’s BLA for 1L Treatment for Non-Squamous NSCLC

Published: May 18, 2021 | Tags: Eli Lilly, Innovent, US, FDA, Sintilimab, Chemotherapy, BLA, Non-Squamous NSCLC

Regeneron and Sanofi Present Results of Dupixent (dupilumab) in P-III VOYAGE Study for Asthma at ATS 2021

Published: May 18, 2021 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, P-III, VOYAGE Study, Asthma, ATS 2021

Abbott Receives CE Mark for Next-Generation Navitor TAVI System to Treat Aortic Stenosis

Published: May 18, 2021 | Tags: Abbott, CE Mark, Next-Generation, Navitor TAVI System, Aortic Stenosis

Charles River to Acquire Vigene Biosciences for $292.5M

Published: May 17, 2021 | Tags: Charles River, Vigene Biosciences, $292.5M

Apellis’ Empaveli (pegcetacoplan) Receives the US FDA’s Approval for Paroxysmal Nocturnal Hemoglobinuria

Published: May 17, 2021 | Tags: Apellis, Empaveli, pegcetacoplan, US, FDA, Approval, Paroxysmal Nocturnal Hemoglobinuria

PerkinElmer to Acquire Immunodiagnostic Systems Holdings for ~$155M

Published: May 17, 2021 | Tags: PerkinElmer, Immunodiagnostic Systems Holdings, ~$155M

Sanofi and GSK Report Results of its COVID-19 Vaccine in a P-II Study Across All Adult Age Groups

Published: May 17, 2021 | Tags: Sanofi, GSK, COVID-19 Vaccine, P-II Study, Adult Age Groups

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

Published: May 17, 2021 | Tags: BMS, Mavacamten, P-III Study, Obstructive Hypertrophic Cardiomyopathy, ACC 2021

Biogen’s BIIB112 (cotoretigene toliparvovec) Fails to Meet its Primary Endpoint in P-II/III XIRIUS Study for XLRP

Published: May 17, 2021 | Tags: Biogen, BIIB112, cotoretigene toliparvovec, Primary Endpoint, P-II/III, XIRIUS Study, XLRP

Related Post: PharmaShots Weekly Snapshots (May 10 – 14, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post